Dishman Carbogen Amcis Ltd. has announced that its wholly owned subsidiary, CARBOGEN AMCIS (Shanghai) Co. Ltd., has received a Drug Manufacturing License from the National Medical Products Administration (NMPA) of China. The license pertains to the company’s manufacturing site located in Shanghai.
This development enables the subsidiary to commence manufacturing operations in line with regulatory compliance under Chinese law. The license was officially granted on April 8, 2025.
In the exchange filing, the company shared, “We are pleased to inform you that yesterday the Company’s wholly owned subsidiary namely CARBOGEN AMCIS (Shanghai) Co. Ltd., has received Drug Manufacturing License from the National Medical Product Administration (NMPA) for its Shanghai, China.”
The approval from NMPA marks a regulatory milestone for the company’s operations in the region and supports its broader international manufacturing and supply capabilities.